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ABSTRACTS1343: B3 CORE BIOPSY SUSPICIOUS OF A PAPILLOMA: HOW SHOULD
WE PROCEED?
Alan G. Dawson, George Ramsay, Tanja Gagliardi. NHS Grampian, Aberdeen,
UK.
Aim: Papillomatous lesions of the breast, with or without atypia, are often
reported as a B3 on core biopsy and proceed to surgical excision. This audit
aimed to retrospectively assess the propensity for neoplasia to occur and
whether surgical excision is appropriate.
Methods: A database of patients with a B3 core biopsy at a single Breast
Unit between October 2005 and April 2012 was searched. Core biopsies of
papillomas scoring B3 with subsequent surgical excision were included.
Demographic parameters including patient age, pre-and post-operative
size, and presence of atypia were recorded. Subsequent development of
cancer was identiﬁed from follow-up data. Analysis of the data was per-
formed using SPSS.
Results: Fifty patients with a median age of 62 years had a median pre-
operative and post-operative lesion size of 12mm and 40mm, respectively.
Atypia was evidenced in 11 patients on core biopsy. DCIS was present in
nine patients at the time of excision and three patients subsequently
developed a cancer. There was a signiﬁcant association between DCIS at
the time of excision and subsequent invasive disease (p¼0.048, Fisher's
exact test).
Conclusion: A B3 core biopsy suggestive of a papilloma without evidence
of atypia can safely be removed by large volume core biopsy.
1372: PATHOLOGICAL EVALUATION OF THE STAGING AXILLARY LYMPH
NODES: A NATIONAL SURVEY IN THE UNITED KINGDOM
Sreekumar Sundara Rajan, Rashmi Verma, Eldo Thomas, Kieran Horgan,
Andrew Hanby, Sally Lane. Leeds Teaching Hospitals NHS Trust, Leeds, UK.
There is ongoing debate about the management of breast cancer patients
with positive staging axillary lymph node (ALN). We aimed to investigate
the practices followed by different pathology laboratories in evaluating
staging ALN.
Methods: A structured questionnaire approved by the NHSBSP pathology
Big 18 committee was circulated amongst all pathologists in the United
Kingdom through the Breast Screening Quality Assurance Reference
Centres.
Results: Amongst 160 respondents, the majority performed SLNB (92%)
for staging. Most laboratories had a protocol for processing staging ALN
(97%). Most laboratories examined the ALN after formalin ﬁxation and
parafﬁn embedding (FFPE) (85.6%). However a few used some initial
intra-operative procedures such as PCR (7.5%), frozen section (3.8%) and
touch imprint cytology (3.1%), with or without subsequent FFPE
examination. Currently 33% perform serial sectioning of the FFPE blocks
with the majority (75%) staining 3 sections using H&E. 67% performed
standard sectioning at 1-2 mm followed by H&E evaluation of
one section. Most units (85%) performed immunohistochemistry eval-
uation only when suspicious cells were detected in the H&E stained
sections
Conclusion: There is considerable variation in the way lymph nodes
are sectioned and evaluated histologically, however majority of the labo-
ratories adhere to the national guidelines for evaluating staging ALN.
1399: THE INFLUENCE OF AGE ON BREAST CANCER TREATMENT
Caroline Mortimer 2, Hirah Rizki 1, Hannah Rizki 3, N. Garg 1. 1 Ipswich
Hospital, Ipswich, UK; 2Anglia Cancer Network, East Anglia, UK; 3 London
School of Economics, London, UK.
Aim: Published literature reports a bias towards under treating elderly
patients with cancer. The aim of this study was to review treatments
offered for primary breast cancer in patients over 70 to assess how age
impacts on access to treatment.
Method: We reviewed data on 651 patients (mean age 80) from eight
breast units across East Anglia between 1st April to 30 September 2010
and 2011. Adult Co-morbidity Evaluation-27 index (ACE-27) and
Nottingham Prognostic Indicator (NPI) values were calculated. Data
were analysed to identify associations between age and treatments
offered.
Results: 451 (mean age 79) patients were suitable candidates for surgery
(ACE-27 score2). 82% were offered surgery (mean age 78). 152 (mean age
77) patients were eligible for chemotherapy (NPI score 3.5 and ACE-27score <3), 15% were offered chemotherapy (mean age 73). Nearly all ER
positive patients received hormonal treatment. In comparison, Herceptin
was administered to 19% of patients who were HER2 positive, with a
decline in use with increasing age.
Conclusion: Overall, we note access to standard treatments declined
signiﬁcantly with increasing age. However, we have not taken into
consideration the performance status of these patients, this may impact on
their suitability for systemic treatments.
1415: CANCELLATION AND NON-ATTENDANCE IN BREAST DAY CASE
SURGERY: ARE ASYMPTOMATIC PATIENTS LESS LIKELY TO ATTEND?
K.L. Whitcroft, E. Martinou, N. Betambeau. St George's Hospital, London, UK.
Aim:High rates of cancellation and patient non-attendance (NA) for breast
day surgery have been anecdotally noted in our institution. We aimed to
determine rates and reasons for cancellation and NA in breast day surgery.
For comparison, lower GI surgery was audited.
Methods: Three months of TheatreMan data and discharge summaries
were retrospectively analyzed for breast and lower GI cancellation/NA
rates. Patients who had not attended were contacted to identify reasons.
Rates were compared using Fisher's exact test.
Results: 42 breast and 73 lower GI patients were scheduled; 6 (14%) and 14
(19%) patients were cancelled and 10 (23%) and 4 (5%) did not attend
respectively. There was signiﬁcantly higher NA in breast patients (18%,
p¼0.019). Cancellation rates were not signiﬁcantly different (5%, p¼0.62).
NAwas most frequently due to social circumstances/perception of need for
operation.
Conclusion: Cancellation rates for both specialties were similar to those
quoted elsewhere. NA was signiﬁcantly higher in breast patients, which
has not previously been explored in the literature. This may be due to low
motivation to attend: breast conditions in day surgery are often benign
and asymptomatic. Additional preoperative interventions (telephone/text
reminders) may be beneﬁcial to ensure attendance and maximize
resources.
1457: DO AXILLARY SENTINEL LYMPH NODE MICROMETASTASES PRE-
DICT INVOLVEMENT OF THE NON-SENTINEL LYMPH NODES IN BREAST
CANCER?
Ashley Topps, Emma de Sousa, Katherine McNamara, Katherine Miller,
Mohammed Absar. North Manchester General Hospital, Manchester, UK.
Aim: Themanagement of patients diagnosed withmicrometastases (tumour
deposits 2.0mm but >0.2mm) on sentinel lymph node (SLN) biopsy is
controversial. In particular, whether a completion axillary node clearance
(cANC) can be avoided in selected patients because of the low prevalence of
metastases in the non-SLNs. Our aim was to investigate whether micro-
metastases found on SLN biopsy predicts metastases in the non-SLNs.
Method: A retrospective review of all SLN biopsies performed between
January 2008 and December 2012 was performed. In patients found to
have micrometastases only on SLN biopsy, the pathology results of the
cANC were obtained.
Results: 450 SLN biopsies were performed. Micrometastases only were
found in 36 patients. 31 of these patients underwent a cANC and non-SLN
metastases were found in 5 (16%). Of the patients with non-SLN metas-
tases, on SLN biopsy they each had only one positive node and on the cANC
specimen the median number of positive nodes found was 2 (range 1 e 3).
It was not possible to identify any speciﬁc criteria that could be used to
exclude certain patients from undergoing cANC.
Conclusions: In patients with micrometastases on SLN biopsy, metastases
in the non-SLNs are relatively common. These patients should therefore
undergo cANC.CARDIOTHORACIC SURGERY
0048: THE USE OF BIOLOGICAL IMPLANTS FOR SOFT TISSUE AND CHEST
WALL RECONSTRUCTION IN THORACIC SURGERY IS SAFE EVEN IN
CONTAMINATED ENVIRONMENTS
Eleanor Atkins, Laura Socci, Anupama Barua, Munib Malik, Anna Raurell,
James Catton, Eveline Internullo, Antonio Martin-Ucar. Nottingham
University Hospitals NHS Trust, Nottingham, UK.
